The remit of the Irish Blood Transfusion Service (IBTS) is to provide a safe, reliable and robust blood service to the Irish health system. Blood, and the products derived from it, are an integral facet of healthcare delivery. A major objective of the IBTS is to ensure that it always has the necessary programmes and procedures in place to protect both donors and recipients of blood and blood products.
In response to a request from the Chief Medical Officer of my Department, the IBTS submitted a paper earlier this year setting out options for future policy in relation to MSM as blood donors. The IBTS was subsequently asked to build on this report, including through appropriate engagement with relevant organisations.
As part of this process the IBTS has engaged professional statistical consultants to develop a model on how to quantify changes in risks to patients from window period HIV transmission, or from the transmission of other emerging infections, in the event of changes in MSM deferral policies. This work, which includes detailed analysis of international evidence with the aim of finalising a specific recommendation, is ongoing. I have asked that this analysis be completed and a report submitted as soon as possible.
The IBTS reviews its existing deferral policies drawing on available scientific evidence, risk assessments, regular review of infectious disease incidence and the practice and experience of other transfusion services. They will continue to ensure that its deferral policies remain current and appropriate for the maintenance of a safe blood supply. The IBTS has informed my Department that a change in the MSM deferral policy is not likely to have a significant impact on the number of donations.
